Peter Greenleaf - Mar 2, 2022 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role: Chief Executive Officer, Director
Signature: /s/ Peter S. Greenleaf
Stock symbol: AUPH
Transactions as of: Mar 2, 2022
Transactions value $: -$108,907
Form type: 4
Date filed: 3/4/2022, 03:11 PM
Previous filing: Jan 31, 2022
Next filing: Mar 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AUPH	Common Stock	Award	$0	+28.3K	+206.04%	$0.00	42K	Mar 2, 2022	Direct	F1, F2
transaction	AUPH	Common Stock	Sale	-$109K	-9.07K	-21.57%	$12.01	33K	Mar 2, 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AUPH	Restricted Stock Unit	Award	$0	+312K		$0.00	312K	Mar 2, 2022	Common Shares	312K		Direct	F4
transaction	AUPH	Stock Option (right to buy)	Award	$0	+534K		$0.00	534K	Mar 2, 2022	Common Stock	534K	$12.01	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
F2	Includes 282 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021.
F3	Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
F4	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
F5	One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.